MDxHealth SA
MDxHealth SA is a commercial-stage precision diagnostics company focused on molecular testing for urologic diseases. MDxHealth SA develops and commercializes diagnostic solutions that help physicians assess the presence, risk, and management of prostate cancer, bladder cancer, and urinary tract infections. Its portfolio includes tissue- and urine-based tests that use genomic, epigenetic, exosomal, and other molecular technologies to support more informed clinical decision-making. The company serves healthcare providers and patients across the United States, Europe, and other international markets, with laboratory and commercial operations supporting the delivery of its tests. MDxHealth SA plays a role in the broader diagnostics market by providing actionable molecular information designed to improve the precision of cancer and infection diagnosis and treatment planning.
$0.21
-$0.40 (-65.73%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-14.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 19.8% YoY with margins expanding 12.4pp.
Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$112M
▲ +19.8% YoY
Net Income (TTM)
-$37M
▲ +12.0% YoY
Op. Margin
-19.06%
▲ +12.4pp YoY
ROIC
-15.04%
▲ +15.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +83.8% YoY
Op. Cash Flow (TTM)
-$5M
▲ +88.5% YoY
Net Debt
$58M
Cash & Equiv.
$29M
3Y CAGR: +42.8%
Continue Research
Is MDxHealth SA (MDXH) overvalued?
MDxHealth SA (MDXH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MDxHealth SA scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is MDxHealth SA a high-quality business?+
MDxHealth SA scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -19.1% operating margin and a -15.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is MDxHealth SA a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MDXH's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Diagnostics & Research
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.